➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Colorcon
AstraZeneca
Johnson and Johnson

Last Updated: November 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tanezumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Tanezumab?

Tanezumab is an investigational drug.

There have been 17 clinical trials for Tanezumab. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2016.

The most common disease conditions in clinical trials are Osteoarthritis, Osteoarthritis, Knee, and Low Back Pain. The leading clinical trial sponsors are Pfizer, Eli Lilly and Company, and Massachusetts General Hospital.

There are ten US patents protecting this investigational drug and one hundred and fifty-four international patents.

Recent Clinical Trials for Tanezumab
TitleSponsorPhase
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to SchwannomatosisPfizerPhase 2
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to SchwannomatosisMassachusetts General HospitalPhase 2
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical StudiesEli Lilly and CompanyPhase 3

See all Tanezumab clinical trials

Clinical Trial Summary for Tanezumab

Top disease conditions for Tanezumab
Top clinical trial sponsors for Tanezumab

See all Tanezumab clinical trials

US Patents for Tanezumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tanezumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Tanezumab   Start Trial Compositions and methods for detecting protease activity in biological systems CytomX Therapeutics, Inc. (South San Francisco, CA)   Start Trial
Tanezumab   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Tanezumab   Start Trial Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same CytomX Therapeutics, Inc. (South San Francisco, CA)   Start Trial
Tanezumab   Start Trial Cell culture medium LA JOLLA BIOLOGICS, INC. (San Diego, CA)   Start Trial
Tanezumab   Start Trial Curcuphenol compounds for increasing MHC-I expression CAVA HEALTHCARE INC. (CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tanezumab

Drugname Country Document Number Estimated Expiration Related US Patent
Tanezumab Australia 2013220749 2032-02-15   Start Trial
Tanezumab Brazil 112014019627 2032-02-15   Start Trial
Tanezumab Canada 2862476 2032-02-15   Start Trial
Tanezumab China 104114705 2032-02-15   Start Trial
Tanezumab China 108570468 2032-02-15   Start Trial
Tanezumab Denmark 2814963 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Colorcon
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.